Cargando…
Molecular Basis for Drug Resistance in HIV-1 Protease
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the inhibitors bind are well characterized. From thi...
Autores principales: | Ali, Akbar, Bandaranayake, Rajintha M., Cai, Yufeng, King, Nancy M., Kolli, Madhavi, Mittal, Seema, Murzycki, Jennifer F., Nalam, Madhavi N.L., Nalivaika, Ellen A., Özen, Ayşegül, Prabu-Jeyabalan, Moses M., Thayer, Kelly, Schiffer, Celia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185577/ https://www.ncbi.nlm.nih.gov/pubmed/21994628 http://dx.doi.org/10.3390/v2112509 |
Ejemplares similares
-
Drug Resistance
Conferred by Mutations Outside the
Active Site through Alterations in the Dynamic and Structural Ensemble
of HIV-1 Protease
por: Ragland, Debra A., et al.
Publicado: (2014) -
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
por: Romano, Keith P., et al.
Publicado: (2012) -
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution
por: Özer, Nevra, et al.
Publicado: (2015) -
Testing the Substrate-Envelope Hypothesis with Designed
Pairs of Compounds
por: Shen, Yang, et al.
Publicado: (2013) -
Efficient
Computation of Small-Molecule Configurational Binding Entropy and
Free Energy Changes by Ensemble Enumeration
por: Silver, Nathaniel W., et al.
Publicado: (2013)